Table 1

	Visit 1			Visit 2			Intra-individual variability
	T4	T8	T12	T4	T8	T12	(%)
Urine volume (mL)	453±272	287±117	331±172	373±179	289±207	384±220	10.5
USG (gmL-1)	1.019±0.009	1.021±0.005	1.018±0.006	1.020±0.007	1.019±0.006	1.016±0.006
Concentration ofsalmeterol (ngmL-1)	0.36±0.19	0.15±0.09	0.10±0.07	0.41±0.28	0.14±0.07	0.08±0.03	43.0
Excretion ofsalmeterol (µg)	0.13±0.04	0.04±0.03	0.03±0.02	0.13±0.06	0.04±0.03	0.03±0.02	12.6
Concentration of a hydroxysalmeterol-(ngmL-1)	2.33±1.43	1.61±1.39	0.68±0.59	2.50±1.49	2.19±1.29	0.92±0.37	43.7
Excretion of α-hydroxysalmeterol(µg)	0.86±0.24	0.39±0.23	0.23±0.21	0.99±0.48	0.55±0.34	0.30±0.16	21.8

Table 1: Urine excretions and urine concentrations of salmeterol and α-hydroxysalmeterol when uncorrected for USG in seven subjects during the first and second visit after inhalation of 100 μg salmeterol. T4: Four hours after administration, T8: Eight hours after administration, T12: Twelve hours after administration. Intra-individual variability is expressed as the mean intra-individual %CV between visits one and two.